3 Growth Companies Insiders Are Betting On
In the wake of recent market turbulence sparked by new tariffs, U.S. indices have experienced significant declines, highlighting the volatility and uncertainty that currently characterize the ...
Hims & Hers Health (NYSE:HIMS) Shares Gap Down on Insider Selling
Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) gapped down before the market opened on Wednesday after an insider sold shares in the company. The stock had previously closed at ...
Endocrinology Advisor10h
Zepbound Now Available Through Hims & Hers
The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.
Health Care Roundup: Market Talk
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner
Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.
‘Hold the Phone,’ Says Morgan Stanley on Hims & Hers Health Stock (HIMS)
Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...
Explore more
Fierce Healthcare22h
DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...
Investor's Business Daily on MSN23h
Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death
Sarepta stock plunged Thursday after European officials put all studies of the company's gene therapy, Elevidys, on hold.
Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty
Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of ...